2 weeks Ago By ABMN Staff
Zynex ( NASDAQ:ZYXI – Get Free Report ) is expected to be posting its quarterly earnings results before the market opens on Monday, April 28th. Analysts expect Zynex to post earnings of ($0.24) per share and revenue of $30.
83 million for the quarter. Zynex has set its Q1 2025 guidance at -0.300- EPS.
Individual interested in participating in the company’s earnings conference call can do so using this link . Zynex ( NASDAQ:ZYXI – Get Free Report ) last released its earnings results on Tuesday, March 11th. The company reported ($0.
02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.11).
The business had revenue of $45.98 million for the quarter, compared to analyst estimates of $53.65 million.
Zynex had a return on equity of 13.05% and a net margin of 2.49%.
During the same quarter in the previous year, the firm posted $0.04 EPS. On average, analysts expect Zynex to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Zynex Stock Performance Shares of ZYXI stock opened at $2.18 on Monday. The company has a current ratio of 3.
94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.
Zynex has a 12-month low of $1.93 and a 12-month high of $12.19.
The company has a market cap of $65.89 million, a price-to-earnings ratio of 14.53 and a beta of 1.
09. The stock has a 50 day simple moving average of $4.40 and a 200-day simple moving average of $6.
84. Analysts Set New Price Targets Read Our Latest Stock Report on Zynex Insiders Place Their Bets In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 3rd.
The shares were sold at an average price of $7.15, for a total transaction of $71,500.00.
Following the completion of the transaction, the chief financial officer now directly owns 10,050 shares in the company, valued at approximately $71,857.50. This trade represents a 49.
88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link . 49.
28% of the stock is owned by company insiders. Zynex Company Profile ( Get Free Report ) Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Read More Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter ..
